Trial Profile
A first-in-human, randomized, placebo-controlled, double-blind, sequential single and multiple ascending dose (SAD/MAD) study with open-label food effect and pharmacodynamic assessment arms to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of ACI-3024
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 01 Apr 2021
Price :
$35
*
At a glance
- Drugs ACI 3024 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; First in man
- Sponsors AC Immune
- 23 Mar 2021 Status changed from recruiting to completed, according to an AC Immune media release.
- 30 Mar 2020 According to an AC Immune media release, results are expected in Q2 2020 and data disclosure by partner is expected in H2 2020.
- 20 Sep 2019 According to an AC Immune media release, company will receive the first milestone payment of CHF30 million from Eli Lilly and Company on or before October 7, 2019 follows initiation of this study.